Breakout Labs
VC Fund
San Francisco, United States
Breakout Labs is a bold re-envisioning of the way innovative science and technology is funded. We invite early-stage companies from around the world to apply for funding of specific milestones on a path to achieving radical advances and far-reaching impact. Our unique revolving fund model allows successful companies to help fund the next generationof innovation.
- Total investments:
- 31
- Last investment:
- Lead investor:
- 39%
- Fund size:
- $60M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Breakout Labs invests in
Stages Breakout Labs invests in
Countries Breakout Labs invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 12 (39%)
- Health Care 6 (19%)
- Medical 5 (16%)
- Manufacturing 5 (16%)
- Therapeutics 4 (13%)
Stage
- Seed 17 (55%)
- Grant 8 (26%)
- Pre-Seed 1 (3%)
- Series A 1 (3%)
- Private Equity 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Hemai Parthasarathy
Scientific Director
|
Scientific Director | Total investments: 1 | Find email | |
Jim O'Neill
Co-Founder
|
Co-Founder | Total investments: 1 | Find email | |
Julia Moore
Portfolio Director
|
Portfolio Director | Total investments: 3 | Find email | |
Lindy Fishburne
Founder & Executive Director
|
Founder & Executive Director | Total investments: 7 | Find email | |
Peter Thiel
Founder & CEO
|
Founder & CEO | Total investments: 272 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Carolina Seed Systems employs cutting-edge genetic technologies to produce market-ready hybrid grain. | $50K / Grant / Apr 04, 2023 | ||
| We are the genome editing company specialized for mitochondrial engineering. We address unmet needs of future food supplies by creating hybrid crop plants to boost their yields to an unprecedented level. The company’s technology creates robust male sterile lines that are ideal over conventional lines because of their stability and elitebackgrounds. This allows the production of non-GM hybrid seeds in crop plants that are currently mostly non-hybrid such as wheat. Our technology solution is expected to fulfill the highest level of public acceptance and aspiration. | $7.9M / Seed / Jul 12, 2022 | ||
| Glyscend develops a revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway. Thecompany's technology is an orally ingestible intestinal coating that prevents the stimulation of duodenal mucosa and inhibits key neurohormonal pathways in the proximal gut. Glyscend is devoted to providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. Meanwhile, the company aims to provide endocrinologists and primary care physicians with the innovative tools they need to treat the disease instead of merely managing it. It was founded in 2014 by co-founders Ashish Nimgaonkar, Michael Parlato, and Pratik Patel. | Seed / Jul 24, 2019 | ||
| We are the genome editing company specialized for mitochondrial engineering. We address unmet needs of future food supplies by creating hybrid crop plants to boost their yields to an unprecedented level. The company’s technology creates robust male sterile lines that are ideal over conventional lines because of their stability and elitebackgrounds. This allows the production of non-GM hybrid seeds in crop plants that are currently mostly non-hybrid such as wheat. Our technology solution is expected to fulfill the highest level of public acceptance and aspiration. | Seed / Apr 30, 2019 | ||
| DropGenie is building connected hardware to automate gene editing. They are accelerating the pace of discovery through the generation of standardized and compatible scientific information. | Seed / Apr 29, 2019 | ||
| Nuclease Probe Technologies develops a phenotypic antibiotic susceptibility test that offers infection testing from blood samples and suggests the appropriate antibiotic for services. Early detection enables veterinarians and physicians to make informed treatment decisions faster and accomplish better outcomes for patients. | $500K / Seed / Mar 07, 2019 | ||
| SciBac is a developer of biotherapeutics intended to treat antibiotic diseases.The company's technology improves beneficial microorganisms using a patented MERGE platform that uses a type of directed evolution to increase therapeutic efficacy. Its first two therapeutics treat chronic infections in cystic fibrosis for Pseudomonas, Staph,Burkholderia, and NTM. | Seed / Oct 10, 2018 | ||
| Orion BioScience specializes in the fields of biotechnology and life science. | Seed / Oct 01, 2018 | ||
| Pelitex is a Product Development and Technology Licensing firm with an IP license to practice and exploit a key disruptive technology called Nanogradient™ materials.Nanogradient™ is a customizable nanoscale alloy that exhibits magnetic, electrical, thermal, mechanical, and anti-‐corrosive properties critical to the performance of products acrossmany market and industry sectors. This technology is utilized to fabricate pure nano-‐scale materials that exhibit high super-‐paramagnetic characteristics as well as extremely high thermal and electrical conductivity. Additionally, the material is exceptionally stable, impermeable, and resistant to corrosion. It can also be functionalized, magnetically tuned, and chemically conjugated to address a number of difficult problems across multiple market segments and industry applications. In broad terms, Pelitex’s technology has performance advantages and competitive attributes in just about any industry area where ferric oxide is used for its magnetic capabilities. The Nanogradient™ technology was developed over the last ten years, and is now a seminal platform technology capable of changing/disrupting the market landscape now occupied by iron oxide, due to its extremely enhanced magnetism, stability, and related attributes. | Seed / Aug 11, 2018 | ||
| Phase Two Chemicals is a clean chemistry company developing breakthrough technology for on-site hydrogen peroxide production. | $350K / Seed / May 09, 2018 | ||
| See all 31 investments → | |||
Co-Investors
Plum Alley
2 deals together
Propel(X)
2 deals together
SOSV
2 deals together
The Thiel Foundation
2 deals together
Alchemist Accelerator
1 deal together
Artis Ventures
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Breakout Labs invest in?
Breakout Labs invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Grant stage. Most of the 31 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Breakout Labs?
Public channels for Breakout Labs include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Breakout Labs?
The team at Breakout Labs includes Hemai Parthasarathy (Scientific Director), Jim O'Neill (Co-Founder) and Julia Moore (Portfolio Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
